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Abstract 
The 2016 International Summit on Intellectual Disability and Dementia examined the 
terminology used to define and report on dementia in publications related to intellectual 
disability (ID) and found mixed uses of terms associated with dementia or causative diseases. It 
noted that language related to dementia in the ID field often lacks precision and could lead to a 
misunderstanding of the condition(s) under discussion. Most articles related to ID and dementia 
reporting clinical or medical research generally provide a structured definition of dementia or 
related terms; social care articles tend toward term use without definition. Toward terminology 
standardization within studies/reports on dementia and ID, the Summit recommended that a 
consistent approach is taken that ensures (a) growing familiarity with dementia-related 
diagnostic, condition-specific, and social care terms (as identified in the working group's report), 
(b) creating a guidance document on accurately defining and presenting information about 
individuals or groups referenced, and (c) that in reports on neuropathologies or cognitive decline 
or impairment, definitions are used and data include subjects' ages, sex, level of ID, residential 
situation, basis for dementia diagnosis, presence of Down syndrome (or other risk conditions), 
years from diagnosis, and if available, scores on objective measures of changing function. 
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Introduction 
Language can and does shape and form our perceptions of a condition or situation.  As 
noted by Alzheimer’s Europe (2013, p. 11), “Some words and metaphors are used liberally and 
paint a very biased picture of dementia, whilst others are avoided and considered demeaning, 
depersonalizing, and insulting. Even standard medical terms are sometimes used with great 
caution due to an awareness of the possible impact on people’s lives and wellbeing.  Words 
clearly matter. They describe, communicate and reinforce our current perceptions of dementia.”   
Nomenclature (or terminology) is a system of names or terms, or the rules for forming 
these terms, in a discipline or field of study.  Reviews of publications (i.e., journal articles, book 
chapters, reports, documents, and plans) involving intellectual disability show varied uses of 
terms associated with dementia or the diseases or conditions causing it (Janicki et al., 2016).  
Terms in use (including dementia, Alzheimer’s, and other similar descriptors) often lack 
precision or consistency and may be used loosely and applied inappropriately.  As with 
publications in the mainstream dementia field, this misuse may be attributed to a lack of 
understanding of the distinction in the terms, the nuances involved with neuropathologies, 
language usage preferences and translational difficulties, or inconsistent use of language, as well 
as absence of or inconsistency in an agreed upon core group of methods used in diagnosis.  
Notably, language related to dementia in the intellectual disability field often lacks precision in 
relation to its peculiarities from onset to progression and often leads to a misunderstanding or 
incomplete representation of the condition(s) under discussion.   
A lack of precision in general applications, as witnessed by recent efforts in the 
mainstream Alzheimer’s and dementia field to address the same issue, appears common.  This 
concern over coherency regarding terminology was discussed by Taylor (2016) at the 
Alzheimer's Disease-Related Dementias 2016 Summit, held in the United States under the 
auspice of the National Institutes of Health (Foundation for the National Institutes of Health, 
2016).  Taylor listed a range of terms that are in use in the field and stimulated a dialogue on 
dementia-related nomenclature regardless of the etiology, specific clinical syndromes, or 
underlying etiologies.  She noted a number of problems stemming from inconsistency in 
terminology, such as Alzheimer’s disease being used synonymously with dementia, low public 
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awareness of other forms of dementia, and a lack of recognition that `Alzheimer’s disease’ 
services are also applicable for those persons affected by non-Alzheimer’s based dementias.   
The problems stemming from inconsistent terminology were also addressed at a meeting 
of the U.S. National Advisory Council on Alzheimer's Research, Care, and Services, which 
under the National Alzheimer's Project Act (NAPA) is responsible for the U.S. National Plan to 
Address Alzheimer’s Disease (Department of Health and Human Services, 2012).  Among the 
issues raised was the rationale for the adoption of updated clinical terminology within the most 
recent Diagnostic and Statistical Manual of Mental Disorders (DSM-5; APA, 2013), and the 
range of terms in use for various dementias, leading to a desire to introduce terminological 
coherency in planning documents (Petersen, 2016).    
The updated clinical terminology refers to the DSM-5’s replacement of the terms ‘mild 
cognitive impairment’ and ‘dementia’ with ‘minor neurocognitive disorder’ and ‘major 
neurocognitive disorder’, recognizing distinctions between distinct or progressive stages.  The 
APA’s DSM-5 changes were designed to recognize a spectrum perspective and varying 
incidence of locus of decline related to different etiologies, and provide more clinical and 
diagnostic precision in identifying variations in the presentation of dementia, particularly when 
dementia was attributed to causes other than Alzheimer’s disease and presenting without the 
classic symptoms inherent in Alzheimer’s (Simpson, 2014).  It also was an attempt to remove 
some of the stigma associated with the word ‘dementia’.  Within the new terminology, the focus 
is on decline rather than deficit in function and the term expands the categories to include other 
etiological conditions (e.g., HIV and acquired brain injuries), which do not necessarily occur in 
association with aging.  Concerns about standardization of language have been increased by this 
change, as the new terms have clinical utility but not general societal usage, and have not yet 
generally been adopted by the major Alzheimer’s or other dementia-related organizations 
internationally in public education and fund raising campaigns.  Introducing the term 
‘neurocognitive’ is also potentially confusing when intellectual disability also has aspects of 
neurocognitive dysfunction, and support for the use of the word ‘disorder’ is questioned in the 
intellectual disability field as it sees the term as stigmatizing (Weymeyer, 2013).  Another 
consideration is that while the new DSM-5 is in use in some Western countries, the use of the 
definitions and diagnostic coding found in the ICD-10 (WHO, 1992) is more prevalent 
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worldwide, leading to some disparities in what terms clinicians and authors may use in medical 
and research reports, respectively. 
 Consequently, the National Advisory Council inserted a recommendation into the 2016 
U.S. National Plan Update that stated that “Emphasis should be given to the standardization of 
terminology in dealing with cognitive and dementing disorders.”  Further, to address this issue 
head-on, the 2016 Update recommended that “an integrated conference should be convened to 
develop consistent language for cognitive disorders among scientists, care providers and the 
public… [and there is a need to] engage all of the stakeholders around these issues to reach a 
consensus for the benefit of persons with dementia, their family members and caregivers, and the 
scientific and service communities” (ASPE, 2016).     
Conveyance of the notion of dementia 
Language usage and terminology is germane to how people affected by dementia are 
viewed to the extent terms used minimize stigma (Garand, Lingler, Conner, & Dew, 2010).   
Clearly, ‘people-first’ language [e.g., adults with dementia] creates more positive imagery and 
can go far to minimize negative perceptions.  Language uses such as ‘adults with dementia’ are 
preferable to terms such as ‘demented, victim, and sufferer’, which tend to be pejorative and 
maximize stigmatization (DEEP, 2015).  Such positive terms also focus on the individuals rather 
than the condition.   
Communicating the definition and process of dementia to people with intellectual 
disability creates a further conundrum.  To enable understanding, language and phrasing needs to 
be at a word-level that organizations communicating with the general public, caregivers, 
advocates, or adults affected by dementia, can effectively convey the concepts associated with 
dementia.  Further, the concepts need to be communicated in a manner so as to explain the 
essence and implications, and convey the seriousness of the condition while not creating 
confusion or undue anxiety.  Siberski (2012) has covered the concern of how the general public 
integrates clinical conceptualizations and reacts to information about diagnoses.   
An aspect of communicating is the ease with which the general population grasps the 
concept behind a clinical disease or neuropathology – so avoiding ‘high science language’ in 
documents directed toward general readership audiences can facilitate understanding.  Using 
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terms and definitions that are in common usage can help to ensure the communication of 
messages. Conversely, creating definitions that minimize the impact of the course and 
eventuality of brain changes leading to dementia can leave conditions untreated (Siberski, 2012).  
To examine the success of concept conveyance to the general public through the level of 
language used, the Summit working group analyzed both the reading ease and grade level of 
definitions conveyed by different dementia, health, and disability organizations when defining 
dementia (see Janicki et al., 2016 for the full report listing the terms and definitions).  Of the 16 
definitions extracted from major dementia-related organization websites and documents, the 
reading ease level ranged from 60.70 to 0.0 (X= 26.68) and the grade level ranged from 7.8 to 
18.6 (X = 13.84).2   It appears that most of the definitions were expressed using complex 
concepts, even when directed at the general public.  For those directed toward professionals, 
despite clarity that dementia is not a disease itself but a group of behavioral and/or function 
symptoms that can accompany certain diseases or conditions, the definitions used were more in 
the realm of technical language.         
Language and terms are a further challenge for intellectual disability organizations, as 
they have to convey both information about the condition and forewarn caregivers of the 
condition’s severity and eventual impact.  How wording is constructed depends on the audience 
and message to be conveyed, and often the explanations lean toward complexity.  This is true 
even among Down syndrome advocacy organizations, where the definitions and explanations of 
dementia (and Alzheimer’s disease) used to inform their constituents tend toward complexity – 
see Table 1.  However, when materials are developed specifically for people with intellectual 
disability, concepts have been explained in a simpler manner.  As an example of a plain language 
definition of dementia, the Down’s Syndrome Scotland’s (n.d.) publication for adults with 
intellectual disability, states “Dementia is an illness in the brain.  It affects many things, but 
mostly the way people remember and do things.” 
Insert Table 1 About Here 
 While it was not the function of this Summit statement to offer a standardized definition 
of ‘dementia’, it was recognized that the condition’s primary features are characterized by the 
                                                          
2 In general, the higher the reading ease score, the more generally understandable wording is; with respect to the 
grade level, lower scores correspond with lower grade level reading abilities. 
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progressive loss of brain function that occurs with certain neuropathological diseases or trauma, 
often associated, but not necessarily related, to aging (others have addressed this characterization 
in depth – see Chertkow et al., 2013; Small et al., 1997).  Such neuropathologies include, among 
others, Alzheimer’s disease, Parkinson’s disease, Pick’s disease, and cerebrovascular accidents.  
The neuropathologies vary and have differing effects – but all have in common the eventual 
expression of progressive behavioral and cognitive changes and decline generally defined as 
dementia.  This expression, in most instances, includes eventual marked memory disorders and 
impaired reasoning, personality and behavioral changes, and loss of self-care, mobility, and 
communication.  The principal aspects of the expression are related to the type of dementia (i.e., 
based on the etiology).  However, it is recognized that features that may initially be taken for 
dementia-like behavioral dysfunctions may instead be the result of adverse drug reactions, 
depression, psychological trauma, or a range of other causes – with their defining feature a 
clearing or reduction of symptoms upon treatment (Desai & Grossberg, 2001).  
Further, it was not the intent of this Summit statement to rectify inconsistencies in 
dementia-associated language usage across the general field of dementia (see Janicki et al., 2016, 
for examples of the variations), but to promote the understanding of the distinctions among the 
terms in prevalent usage, and advance the application of precise usage and agreement on 
dementia-related terms that are commonly used in association with intellectual disability.  Such a 
result would advance clearer differentiation and appropriate usage of clinical terms such as: 
dementia, Alzheimer’s disease, cognitive impairment, Alzheimer’s disease spectrum, pre-clinical 
Alzheimer’s disease, dementia due to Alzheimer’s disease, mild cognitive impairment due to 
Alzheimer’s disease, early versus late onset disease, and mild, moderate and advanced dementia 
(Alzheimer’s disease), and others.  We are not proposing a standard definition of dementia or 
acceptance of a range of associated terms that would be applied in work in intellectual disability 
– no such consensus on term usage exists in the general dementia literature or policy documents 
(save for those noted earlier in the DSM-5 (APA, 2013) or ICD-10 (WHO, 1992) for diagnostic 
purposes). We are suggesting that workers/researchers/educators do provide an operational 
definition of dementia of their choosing so as to offer readers a clear understanding of the 
variables and notions related to the population being described. 
Applications of terms 
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 How terms are used can affect clarity in understanding which subject population is being 
referenced and what conditions are being discussed.  In a sampling of available articles and 
reports related to intellectual disability and dementia undertaken by the Summit’s working 
group, term-usage was found to be variable and at times less than clear (see Janicki et al., 2016).  
Authors in general used ‘dementia’ as a common term defining the nature of the condition, there 
was often mixed reference to Alzheimer’s disease, dementia of the Alzheimer’s type, and generic 
‘dementia,’ without linkage to standard definitions (such as those in the DSM-5 and ICD-10). 
There was also an absence of defining whether the dementia being reported was progressive.  
While the usage served the intended purpose – of defining the general concern of the article – it 
left open interpretations of how the condition was identified in the subjects, to what degree it was 
progressing (or if progression was a concern), and what may have been the underlying 
neuropathology.  Some of these data may not always be readily available in social care research, 
but should be available in medical/health related research and in articles advancing or relying 
upon standardized assessments. 
Defining the subject population also has import and implications for research related to 
dementia in the intellectual disability field.  The Summit working group’s study also noted the 
high preponderance of articles in the intellectual disability and dementia literature that focused 
predominantly on Down syndrome (Janicki et al., 2016). Given the high risk for Alzheimer’s 
disease among adults with Down syndrome this is not unexpected.  However, it is important that 
authors are clear when reporting results and generalizing effects that the information provided 
relates to dementia in adults with Down syndrome (if this was the subject population), as there 
may be differential patterns of onset, effect, and mortality in the greater population of adults with 
intellectual disability who do not have Down syndrome.  Often in articles and reports the number 
or percentage of subjects with Down syndrome (and their sex and ages) is not identified within 
the study population; this may confound generalizability unto the greater population of adults 
with intellectual disability, and misinform on the epidemiology of dementia. Also, as most 
studies involving adults with Down syndrome relate to dementia of the Alzheimer’s type, this 
also should be noted in the subject descriptions, and/or any variations in forms of dementia 
should be noted.  Such detail will also highlight the number of study participants where an 
accurate diagnosis has not been made and the type of dementia is not known.  
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As what is popularly considered chronological aging can span 30 or more years, 
dementia-oriented studies should consider grouping data into age categories that reflect the 
younger-older and older-older grouping of subjects.  Given that early-onset dementia is prevalent 
in adults with Down syndrome, the age span for younger-older may begin in the 40s and the 
older-older with age 60.  When adults absent Down syndrome are the focus of studies then 
younger-older may begin in the 60s, and later age groupings may include those aged 75 and 
older – similar to general population reports.  Such groupings can help establish patterns in 
incidence, related features, such as co-morbidities, and staging.  Also, when reporting subject 
recruitment, methodology sections in reports should contain concise definitions of dementia and 
at what dementia stage recruitment occurred.  Although, identifying stage of dementia can be 
confounded by the degree and nature of the intellectual disability, efforts should still be made to 
define it as accurately as possible (Krinsky-McHale & Silverman, 2013).  When reporting 
staging, terminology should reflect the spectrum of cognitive impairment when that is known in 
the study subjects. 
The Summit working group observed that most articles related to intellectual disability 
and dementia were using prevalent dementia-related terms, rather than the DSM-5 terminology 
(e.g., neurocognitive disorders); this is also observed in the general dementia literature.  Also, 
that the articles reporting assessment and clinical or medical research were more apt to provide a 
definition of dementia or related terms, while social care articles tended to only use the term 
itself and not define it or provide substantiation of study subject diagnoses.  The working group 
suggested that it would increase research and practice recommendation utility if social care 
articles also provided definitions and the basis for ascribing dementia to the persons in the 
studies, thus offering more precision and permitting cross-article comparisons and contrasts.  
Further, as many of the articles examined failed to define the subject population with respect to 
age, sex, level of intellectual disability, etiology, and other demographic variables, the 
standardization of reporting subject information recommended here would also increase utility.  
Also, judicious use of common terms among key words in manuscript submissions will aid in 
locating relevant articles following publication (e.g., Alzheimer’s disease, cognitive impairment, 
dementia, Down syndrome, neurocognitive disorders, neuropathology, intellectual disability, 
etc.) 
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Commentary 
 The intent of this Summit statement is to reflect discussion at the international meeting in 
Scotland to promote the understanding of the distinctions among terms in prevalent use with 
respect to intellectual disability and dementia, and to advance usage that more accurately reflects 
the concepts cited, and agreement on commonly used dementia and intellectual disability-related 
terms. Terminology needs precision to accurately convey the conditions and services being 
discussed.  The Summit proposes that authors, irrespective of the focus of the article, provide 
operational definitions of conditions being considered, ancillary demographic and clinical data, 
study population parameters, particularly the numbers (and percentages) of subjects with Down 
syndrome, and information about how diagnoses were obtained, as well as the protocols and 
instruments employed. In social care articles, authors should offer a definition or explanation of 
the program(s) or service(s) under discussion.  Readers would then be offered a clearer 
understanding of the population being described and the features being studied, and thus 
replication in future studies and comparisons across existing studies would be facilitated.   
Recommendations 
The Summit goals were to address issues associated with nomenclature (or terminology), 
seek agreement on a common taxonomy related to cognitive impairment and dementia among 
persons with intellectual disability and encourage use of standardized terminology within studies 
and reports on dementia and intellectual disability.  With this in mind, the Summit recommends: 
● To promote positive imagery, organizations, researchers, educators and workers adopt 
and use image enhancing language when describing persons with intellectual disability 
affected by dementia and avoid language that stigmatizes or dehumanizes; 
● To promote standardized understanding of the meaning of terms used to describe 
services and conditions related to dementia and intellectual disability, that a taxonomy be 
adopted for general use.  A taxonomy of unvetted terms related to defining dementia and 
dementia services prevalent in dementia and intellectual disability publications is found 
in the appendix of the full Summit report (see Janicki et al., 2016) and can offer user 
guidance on the development of a formal taxonomy; 
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● To help with reporting and describing events or conditions related to intellectual 
disability and dementia, that a guidance document be created on accurately defining and 
presenting information about individuals or the group being referenced to include both 
formal diagnostic criteria and general definitions of various dementias.  We recommend 
that the guidance document be supported by a consortium of associated intellectual 
disability, gerontology, and dementia groups, and appear in a relevant publication (for 
archival purposes); and    
● To standardize reporting of subjects and outcomes from studies, researchers, educators 
and workers follow recommendations for harmonizing data in reports addressing 
neuropathologies, behavioral and functional changes, cognitive decline or impairment.  
Such reports should use recommended definitions and at a minimum include the subjects’ 
ages, sex, level of intellectual disability, residential situation, co-morbidities, basis for 
dementia diagnosis, presence of Down syndrome (or other risk condition), years from 
diagnosis, and if available, scores on an objective measure of changing function from a 
recognized and validated dementia scale.   
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Table 1:  Statements related to dementia/Alzheimer’s disease by major English-language Down syndrome organizations 
 
Source Website Statement 
Down Syndrome 
International 
(INT) 
https://ds-int.org/resource/adults-18-
ageing 
“Dementia is a frequently voiced concern about people with Down syndrome. There is a 
tendency for people with Down syndrome to develop dementia at a younger age than in 
the general population. However, research indicates that the overall percentage of adults 
with Down syndrome who develop dementia is similar to that of the population who do 
not have Down syndrome.  It is not inevitable that those with Down syndrome will 
develop dementia.” 
Down Syndrome 
Research 
Foundation 
(Canada) 
http://www.dsrf.org/information/down-
syndrome-and-alzheimer-s/ 
“People with Down syndrome (DS) are at an increased risk of Alzheimer’s disease (AD) 
because of the presence of three copies of chromosome 21. Chromosome 21 contains 
over 300 genes including several that are associated with AD; the amyloid precursor 
protein gene (APP) is one of these genes. This and other genes are associated with the 
plaques that accumulate in the brain as well as inflammation and oxidative stress that 
takes place early in development and progressively leads to mitochondrial impairment, 
degeneration of neuronal pathways, accelerated aging and loss of brain cells in the 
cerebral cortex and hippocampus. Although in DS AD brain pathology is frequently seen in 
the 40’s not everyone with DS exhibits the clinical signs of Alzheimer’s, which usually 
happens in the 50’s and 60’s, even though all have the brain pathology.” 
Down’s 
Syndrome 
Association (UK) 
http://www.downs-syndrome.org.uk/for-
families-and-carers/health-and-well-
being/getting-older/alzheimers-disease/ 
“Alzheimer’s disease is a type of dementia that gradually destroys brain cells, affecting a 
person’s memory and their ability to learn, make judgments, communicate and carry out 
basic daily activities.  Alzheimer’s disease is characterized by a gradual decline that 
generally progresses through three stages: early, middle and late stage disease. *** 
Dementia is not a disease in its own right. Dementia is an umbrella term covering more 
than 100 different conditions associated with a cognitive decline. One of these conditions 
is Alzheimer’s disease.” 
National Down 
Syndrome 
Society (USA) 
http://www.ndss.org/Resources/Aging-
Matters/Alzheimers-Disease/An-
Introduction-to-Alzheimers-Disease/ 
“Alzheimer’s disease is a type of dementia that gradually destroys brain cells, affecting a 
person’s memory and their ability to learn, make judgments, communicate and carry out 
basic daily activities. Alzheimer’s disease is characterized by a gradual decline that 
generally progresses through three stages: early, middle and late stage disease. These 
three stages are distinguished by their general features, which tend to progress gradually 
throughout the course of the disease. Alzheimer’s disease is not inevitable in people with 
Down syndrome. While all people with Down syndrome are at risk, many adults with 
Down syndrome will not manifest the changes of Alzheimer’s disease in their lifetime. 
Although risk increases with each decade of life, at no point does it come close to 
reaching 100%. *** Estimates show that Alzheimer’s disease affects about 30% of people 
with Down syndrome in their 50s. By their 60s, this number comes closer to 50%.” 
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Down Syndrome 
Australia (AUS) 
http://www.downsyndrome.org.au/docu
ments/Ageing_Resource_Health_Check.p
df 
“Alzheimer’s disease is a progressive degenerative condition of the brain that results in a 
gradual change, over years, in a person’s ability to think, remember and perform tasks of 
daily living. In ways that scientists don’t yet understand, the extra copies of genes present 
in people with Down syndrome cause developmental problems and health issues. 
Scientists think that the increased risk of dementia in individuals with Down syndrome 
may also result from the extra gene present on chromosome 21. Some studies suggest 
that 30 per cent of people with Down syndrome aged in their 50’s have Alzheimer’s 
disease and more than 75 per cent aged 65 and older have Alzheimer’s disease.” 
 
